
The Longevity Show with Dr. Hillary Lin
My LDL Was 192. Then I Found the First PCSK9 Pill.
My LDL was 192 even though I felt healthy. That result sent me into the story of PCSK9—a protein discovered outside cholesterol research that became the target of injections, RNA silencing, the first oral PCSK9 inhibitor, and now one-time gene-editing experiments. This episode follows the human genetics, LDL-receptor biology, and three engineering problems behind Lipfendra/enlicitide. The pill has proven potent LDL and ApoB lowering; its dedicated cardiovascular-outcomes trial is still ongoing. : . , , . Chapters : 00:00 The Inherited Risk: My LDL Was 192 and the First Oral PCSK9 Is Here 02:36 Nature’s Human Experiment: The Dallas Heart Study & The 88% Risk Drop 05:40 The Zero-PCSK9 Human: What Living with an LDL of 14 Proves 07:10 The Disposal Tag: How PCSK9 Destroys Your Artery Clearance 08:42 The Evolution of PCSK9 Inhibitors: From Antibodies to RNA 12:02 Evolution in a Test Tube: Engineering the First Oral PCSK9 Pill 16:04 The Practical Inversion: Why a Daily Pill Can Be Harder Than an Injection 18:04 One Injection for Life: The Promise and Risk of Permanent Gene Editing 21:12 What This Means for You: Managing Family History, Risk, and Daily Reality


